Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.87 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.65 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.65 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117118 | 0.98 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL5139685 | 0.98 | LTA4H (0.84) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL229697 | 0.98 | LTA4H (0.90) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL227425 | 0.96 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL227976 | 0.96 | LTA4H (0.87) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL27711502 | 0.90 | ATM (0.88) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL18824776 | 0.89 | ATM (0.87) | LTA4HPTGS2ATML3MBTL1KDM4E | |
| SCHEMBL7139221 | 0.89 | LTA4H (0.75) | LTA4HPTGS2ATML3MBTL1PSMB1 | |
| SCHEMBL491581 | 0.88 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 | |
| SCHEMBL1776837 | 0.88 | ATM (0.90) | LTA4HPTGS2ATML3MBTL1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | disclosed |
| US-7105679-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M | 2006-09-12 | — | — | US | disclosed |
| EP-1467998-B1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | KANOJIA RAMESH M (US) | 2004-12-23 | — | — | US | disclosed |
| EP-0863755-B1 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1244655-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | disclosed |
| US-6620837-B1 | 1-Benzothiophene derivatives | ELI LILLY AND COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6284756-B1 | ANTICOAGULANT | ELI LILLY AND COMPANY | 2001-09-04 | — | — | US | disclosed |
| US-6265575-B1 | THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6251921-B1 | ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0863755-A4 | ANTITHROMBOTIC DIAMINES | LILLY CO ELI (US) | 1999-01-20 | — | — | EP | disclosed |
| EP-0863755-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997025033-A1 | ANTITHROMBOTIC DIAMINES | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259915-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | LTA4H 1473/4885PTGS2 437/4885ATM 4284/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | LTA4H 1473/4885PTGS2 437/4885ATM 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.